Skip to main content

Anaplastic Astrocytoma

3
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Orbus Therapeutics
Orbus TherapeuticsCA - Palo Alto
1 program
1
EflornithinePhase 31 trial
Active Trials
NCT02796261Unknown343Est. Jun 2023
Isarna Therapeutics
Isarna TherapeuticsGermany - Munich
1 program
1
trabedersenPhase 3RNA Therapeutic1 trial
Active Trials
NCT00761280Terminated27Est. Jun 2012
Pfizer
PfizerNEW YORK, NY
1 program
1
Sunitinib MalatePhase 21 trial
Active Trials
NCT00606008Completed30Est. Aug 2012
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
TemozolomidePHASE_31 trial
Active Trials
NCT00717210Completed318Est. Mar 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Orbus TherapeuticsEflornithine
Isarna Therapeuticstrabedersen
Heidelberg PharmaTemozolomide
PfizerSunitinib Malate

Clinical Trials (4)

Total enrollment: 718 patients across 4 trials

NCT02796261Orbus TherapeuticsEflornithine

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

Start: Jul 2016Est. completion: Jun 2023343 patients
Phase 3Unknown
NCT00761280Isarna Therapeuticstrabedersen

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Start: Dec 2008Est. completion: Jun 201227 patients
Phase 3Terminated
NCT00717210Heidelberg PharmaTemozolomide

Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide

Start: Jun 1999Est. completion: Mar 2008318 patients
Phase 3Completed
NCT00606008PfizerSunitinib Malate

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

Start: Mar 2007Est. completion: Aug 201230 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.